Friday 6 November 2026 Export VCYT’s income statement to Excel — free account

Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.

Revenue: +15.1%
EPS: +62.5%
Free cash flow: −9.63%

Quarter to September 2026, against a year earlier

24.42 0.42 +1.75%

Follow VCYT

Alert me

Market cap: $1.9B
P/E: 15.2×
Fwd P/E: 45.2×
Dividend yield: —
F-score: 8/9
Altman Z: 21.08
Beneish M: −2.66
Dividend safety: n/a

Overview

Veracyte, Inc. (VCYT) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Veracyte, Inc. (VCYT) trades at a price to free cash flow of 12.0×. Over the past ten years it has ranged from 0.0× (March 2023) to 273× (June 2023); the current reading is higher than 70% of that period. That is below the Diagnostics & Research industry median of 33.5× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VCYT/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Veracyte, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VCYT/metrics/price-to-free-cash-flow">Veracyte, Inc. (VCYT) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	26.1×	(44.96%)
FY2024	47.5×	(18.30%)
FY2023	58.1×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	22.9×	(19.12%)
Jun 2026	28.3×	71.57%
Mar 2026	16.5×	(36.88%)
Dec 2025	26.1×	(5.06%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 273×

Ten-year median 0.0×

Current reading's percentile 70

Company	Price to free cash flow
WGS GeneDx Holdings Corp. compare	n/m
NEO NeoGenomics, Inc. compare	n/m
GRAL GRAIL, Inc. compare	n/m
ADPT Adaptive Biotechnologies Corporation compare	n/m
VCYT Veracyte, Inc.	12.0×
SHC Sotera Health Company compare	33.5×
CDNA CareDx, Inc. compare	68.9×
BLLN BillionToOne, Inc. compare	156×
RDNT RadNet, Inc. compare	189×
Diagnostics & Research industry median	33.5×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Veracyte, Inc. (VCYT) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on VCYT

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on VCYT

Stockrow Weekly